Summary. Nineteen patients, of whom ten had bean previously treated with and failed on other oral antidiabetie drugs, were included in a cross-over trial in order to compare the efficacy of glipizide with placebo in the ease of the newly diagnosed patients and with previous therapy in established diabetics. Glipizide was more effective than placebo in all cases and provided excellent or good control in eight out of the nine newly diagnosed patients. In three out of the ten previously treated patients, glipizide improved control. The drug was well tolerated.
Glipizide is a sulfonyleyelohexylurea derivative and its mode of action has been described by Ambrogi et al. [1, 2, 3] . The drug has proved to be a potent hypoglycemia agent. No toxic effects were observed during long-term treatment in animals with doses up to 60 times the optimal therapeutic dose. Neither have any teratogenie effects been observed.
Clinical material
19 patients, 9 women and 10 men, have been treated with glipizide. All were out-patients. The material was divided into two groups.
Group I 7 women and 3 men, average age 56 years, had earlier been treated with sulfonylurea drugs. Four of these had been treated with a combination of phenformin and sulfonylnrea. Nine of the patients were soiealled secondary failures. One patient had nausea with the previous therapy.
Group II 2 women, 7 men, average age 55 years, with newly diagnosed diabetes, not controlled by diet alone.
Methods
The glipizide trial was performed as a cross-over study. In group I glipizide was compared with placebo and earlier antidiabetic agents given according to one of two alternatives:
1. placebo/4 weeks/ --glipizide/3 months/ --placebo/4 weeks/ --earlier used drug/3 months/, or 2. placebo/4 weeks/--earlier used drug/3 months/ --placebo/4 weeks/ --glipizide/3 months/.
Group II was treated according to one of the following 2 alternatives:
1. diet/3 weeks/--glipizide/2 months/--placebo/2 months/ --glipizide/2 months/, or 2. diet/3 weeks/--, placebo/2 months/--glipizide/2 months/ --placebo/2 months/.
All patients had received diet instruction and remained on the same calorie consumption during the whole study. Patients on treatment with digitalis, diuretics and/or antihypertensives remained on the same dose during the whole trial period. Patients treated with phenformin remained on the same dose even during "placebo periods".
Glipizide was given as a single dose up to 10 mg and thereafter in 2 doses morning and evening. The patients were examined fasting in the morning, initially every week and then at intervals of 2--3 weeks. At every visit fasting blood glucose (ace. to Marks -59 [4] ), urine glucose (tested with Clinitest, Ames) and body weight were checked. Determinations of blood picture, liver and kidney functions, serum electrolytes, serum cholesterol (ace. to Huang [5, Ness [6] and serum triglycerides (ace. to Laurell 66 [7] ) were performed. In addition, the fundi were inspected and an ECG performed.
Results
In group I (Table 1 ) "good control" was obtained in 3 patients who had failed on other antidiabetie therapy. In 4 patients glipizide treatment resulted in impaired control. In three of these patients [3, 5, 10] insulin therapy is now necessary. In group I there are no statistically significant differences between blood and urine glucose during the different periods.
In group II "excellent control" was obtained with glipizide in 5 patients, "good control" in 3 patients Table 1 . Table 2 . and "fair control" in 1 patient. With diet and placebo "good control" was achieved only in 2 patients, and in the remaining eases satisfactory control was not obtained (Table 2 ). In group II there are significantly lower blood glucose values on glipizide therapy than on placebo (0.01 < p < 0.001). Urine glucose disappeared during glipizide therapy in all eases.
Group I. Previously treated patients

Group II. Newly diagnosed "patients
Side effects
After 2 weeks treatment with glipizide at a dose of 5 rag, one man in group II had hypoglycemic side effects approximately 3 h after breakfast and glipizide. Rapid relief was obtained following the intake of food. With the same dose of glipizide the patient has subsequently been subjectively well. Consecutive blood glucose determinations up to 3--4 h after breakfast have not shown any excessively low values. Glipizide was well tolerated by the remaining patients in both groups. Gastrointestinal side effects have not been observed.
Blood picture, liver and kidney function as well as electrolytes have remained unchanged. Serum cholesterol and serum triglyeerides and also blood pressure have shown a tendency to decrease during treatment. The appearance of the fundi and ECG have remained unchanged.
